Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company focused on developing innovative therapies for life-threatening diseases. This page provides investors and healthcare professionals with timely updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of Gilead's press releases and news, including updates on antiviral therapies, oncology research, and clinical trial results. Our curated collection features earnings announcements, partnership details, and progress reports on treatments for HIV, hepatitis, and emerging cancer therapies.
Stay informed about critical developments through verified updates on FDA approvals, research collaborations, and therapeutic advancements. All content is organized chronologically for quick reference, with clear sourcing to ensure transparency.
Bookmark this page for streamlined access to Gilead Sciences' official communications and third-party analysis. Regularly updated to reflect the company's evolving pipeline and market position, this resource supports informed decision-making for stakeholders at all levels.
Gilead Sciences, a biopharmaceutical company focused on developing innovative medicines for unmet medical needs, emphasizes the importance of removing barriers to healthcare access. Johanna Mercier, Chief Commercial Officer, highlights Gilead's efforts to improve health equity and increase access to life-changing therapies. These initiatives align with the company's commitment to responsible business practices.
Gilead operates in over 35 countries globally, with its headquarters in Foster City, California. The company's mission is to transform and simplify care for people with life-threatening illnesses worldwide, focusing on areas of unmet medical need.
Gilead Sciences has released a children's book titled 'The Adventure Jar' as part of its ongoing commitment to support families affected by metastatic breast cancer (MBC). The book, created in partnership with the MBC community, illustrates how one family navigates the challenges of a cancer diagnosis while finding joy in their time together. This initiative aims to provide resources and support for people living with MBC, particularly focusing on the impact on children.
Gilead Sciences is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines in areas of unmet medical need. With operations in over 35 countries and headquarters in Foster City, California, Gilead strives to transform and simplify care for people with life-threatening illnesses worldwide.
Gilead Sciences (GILD) has announced its executives' participation in three upcoming investor conferences in September:
- Wells Fargo Healthcare Conference on September 4
- Morgan Stanley Annual Global Healthcare Conference on September 5
- Baird Global Healthcare Conference on September 10
Live webcasts will be available on Gilead's investor page, with replays accessible for at least 30 days. Gilead, a biopharmaceutical company with over three decades of experience, focuses on developing innovative medicines for life-threatening diseases like HIV, viral hepatitis, COVID-19, and cancer. Operating in more than 35 countries, Gilead is headquartered in Foster City, California.
Forbes has recognized Gilead Sciences as one of America's Best Employers For Women for the third consecutive year. This recognition highlights Gilead's commitment to fostering an inclusive workplace where women can make a meaningful impact.
Gilead emphasizes creating a culture that champions women and offers competitive benefits focused on employee wellbeing. The company's approach aligns with its mission to drive innovation and create a healthier world for all people.
This acknowledgment by Forbes underscores Gilead's ongoing efforts to provide an environment where women can thrive professionally and contribute significantly to the company's goals in the biopharmaceutical industry.
Dr. Summer Sitima, Gilead's Commercial Operations Lead in South Africa, shares her personal journey and the company's initiatives to combat HIV in Africa. Growing up during the HIV epidemic, Summer's experiences led her to pursue a career in healthcare. Today, she leads efforts to address the high rate of HIV diagnoses among adolescents in South Africa.
Gilead collaborates with partners to provide HIV testing, treatment, and education. Innovative programs include training barbers and hairdressers as HIV educators, sponsoring charity runs for medical education, and implementing tree-planting initiatives to improve access to healthcare services. These efforts aim to reduce stigma, increase awareness, and improve access to care in resource- African countries where millions live with HIV and hepatitis.
Gilead Sciences has received accelerated FDA approval for Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) in adults. The approval is based on the Phase 3 RESPONSE study, where 62% of Livdelzi patients achieved the primary endpoint versus 20% on placebo. Livdelzi demonstrated significant reductions in alkaline phosphatase (ALP) levels and pruritus (itching), key markers of PBC progression. As the first and only treatment to show statistically significant improvements in both pruritus and cholestasis markers, Livdelzi challenges the current PBC standard of care. The drug's continued approval may depend on confirmatory trials demonstrating clinical benefits in survival or prevention of liver decompensation.
Gilead Sciences (Nasdaq:GILD) and the Elton John AIDS Foundation announced a five-year, $25 million extension of their RADIAN partnership to address the growing HIV crisis in Eastern Europe and Central Asia (EECA). The initiative aims to support local organizations and expand its geographic focus to include countries hosting Ukrainian refugees. Key highlights:
- EECA is one of the few regions where HIV is increasing, with new diagnoses up 20% and AIDS-related deaths up 34% since 2010.
- RADIAN has reached over 271,000 people with HIV services, provided 114,000+ HIV tests, and (re-)initiated 26,500+ people on antiretroviral therapy since 2019.
- The extension will focus on vulnerable populations and introduce an innovation fund for creative HIV response solutions.
This partnership aims to combat the escalating HIV crisis in EECA, exacerbated by conflict, anti-LGBTQ+ legislation, and stigma.
Gilead Sciences (GILD) reported strong Q2 2024 results with total revenue increasing 5% to $7.0 billion. Product sales excluding Veklury grew 6% year-over-year to $6.7 billion, driven by HIV, Liver Disease, and Oncology. Biktarvy sales increased 8% to $3.2 billion, while Oncology sales rose 15% to $841 million. Diluted EPS was $1.29, up from $0.83 in Q2 2023, primarily due to lower operating expenses and higher revenues. Non-GAAP diluted EPS increased to $2.01 from $1.34. The company's cash position decreased to $2.8 billion, mainly due to the $3.9 billion acquisition of CymaBay Therapeutics. Gilead updated its full-year 2024 guidance, maintaining product sales projections but adjusting EPS expectations.
Gilead Sciences is partnering with local German organizations to close the HIV diagnosis gap, particularly in rural and migrant communities. Germany has achieved 90% diagnosis and treatment rates for people living with HIV, but aims to reach the UNAIDS goal of 95% by 2025. Gilead's HIVISION100 initiative brings together 45 HIV experts to share best practices and improve testing accessibility.
One key partner, AIDS-Hilfe Krefeld, utilizes a mobile clinic to offer HIV and STI testing in resource- areas. Anja Wiese, an educator for the organization, believes that collaborative efforts can help Germany achieve 100% diagnosis rates. Gilead's innovations have transformed HIV from a fatal disease to a chronic and preventable condition for many, and the company is now focused on helping end the HIV epidemic globally.
The Center for Disease Analysis Foundation (CDA Foundation) has awarded $1.8 million in grants to 11 organizations as part of the CDAF-Relink program. This initiative aims to reconnect US-based individuals infected with hepatitis C (HCV) or hepatitis B (HBV) to care. The program is sponsored by an $8 million grant from Gilead Sciences (GILD). The second round of grants builds on the successes and lessons learned from the first round, implementing evidence-based approaches and emphasizing knowledge sharing. The goal is to link an estimated 5,400 diagnosed but untreated HCV and HBV infected individuals back into physicians' care. The third round of proposals will open in August 2024, with priority given to state health agencies.
